Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -$3.0 million.

  • Aclaris Therapeutics' Cash from Financing Activities fell 13936.36% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 1424940.00%. This contributed to the annual value of $74.5 million for FY2024, which is 179.10% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Cash from Financing Activities is -$3.0 million, which was down 33,722.22% from -$9,000 recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Cash from Financing Activities high stood at $135.9 million for Q2 2021, and its period low was -$11.6 million during Q3 2021.
  • Over the past 3 years, Aclaris Therapeutics' median Cash from Financing Activities value was -$11,000 (recorded in 2024), while the average stood at $7.9 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Cash from Financing Activities soared by 152,104.08% in 2024, and later plummeted by 13,936.36% in 2025.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Cash from Financing Activities stood at -$2,000 in 2021, then soared by 1,950.00% to $37,000 in 2022, then skyrocketed by 32.43% to $49,000 in 2023, then spiked by 152,104.08% to $74.6 million in 2024, then slumped by 13,936.36% to -$3.0 million in 2025.
  • Its last three reported values are -$3.0 million in Q3 2025, -$9,000 for Q2 2025, and -$275,000 during Q1 2025.